CRRT

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
ODD, Research, Hyperphosphatemia, DGF, CRRT, ERA, Administration, Congress, Conference, OLC, CKD, Patient, AKI, National Kidney Foundation, Mitochondrion, NDA, Kidney transplantation, Insurance, Kidney disease, Critical care, Acute kidney injury, Clinical trial, Therapy, Drug development, Safety, Chronic kidney disease, Dialysis, LOS, Research and development, SAD, FDA, KATP, Food, Pharmaceutical industry

LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.

Key Points: 
  • LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.
  • Completed a private placement with new and existing healthcare institutional investors that generated $50 million in gross proceeds to Unicycive.
  • Cash Position: As of December 31, 2023, cash and cash equivalents totaled $9.7 million.
  • Subsequent to year end, in March 2024, Unicycive completed a private placement of preferred stock which generated $50 million in gross proceeds.

Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference

Retrieved on: 
Wednesday, March 13, 2024
CRRT, DGF, Conference, AKI, Patient, Kidney transplantation, MD, Kidney disease, Critical care, Acute kidney injury, Therapy, Safety, Kidney, LOS, SAD, FDA, Administration, Pharmaceutical industry

LOS ALTOS, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two presentations related to UNI-494 were presented on March 12, 2024 at the 29th International Conference on Advances in Critical Care Nephrology AKI and CRRT 2024.

Key Points: 
  • “We are excited about the tremendous progress we have made with our second clinical development asset, UNI-494,” said, Shalabh Gupta, MD, Chief Executive Officer of Unicycive.
  • The oral presentation, entitled, “Intravenous Administration of UNI-494 Ameliorates Acute Kidney Injury in Rat Model of Delayed Graft Function” was delivered by Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive Therapeutics.
  • The study concluded that UNI-494 is a potential candidate for prevention of DGF and other AKI clinical conditions.
  • The poster, entitled, “UNI-494 Phase 1 Safety, Tolerability and Pharmacokinetics: Trial in Progress” was presented by Guru Reddy, PH.D., Vice President of Preclinical R&D, Unicycive Therapeutics.

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

Retrieved on: 
Wednesday, March 13, 2024
Health, Infectious Diseases, Surgery, General Health, Clinical Trials, Pharmaceutical, Biotechnology, CRRT, Conference, Rat, Disease, AKI, TLR4, Acute kidney injury, Immunity, Toll-like receptor 4, Poster, Animal, Kidney

Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI.

Key Points: 
  • Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI.
  • A copy of the presentation and poster presented at the AKI and CRRT 2024 Conference can be found on Revelation’s website .
  • In addition to clinical observation, rats were evaluated for markers of kidney function at 24 and/or 72 hours post-surgery, and markers of kidney damage at 72 hours post-surgery.
  • Reduced overall damage (necrosis) of the cortical (p

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Retrieved on: 
Wednesday, March 13, 2024
CRRT, Conference, Pneumonia, CRAC, Disease, Incidence, GFR, AKI, Patient, Physiology, COVID-19, Renal artery, Biomarker, Hemofiltration, T helper 17 cell, Mortality, Indiana University, Cell biology, Glomerular filtration rate, Respiratory failure, Doctor of Philosophy, Acute kidney injury, Ischemia, Kidney, Poster, Stage 2, Blood, Animal, Hospice and palliative medicine, Pharmaceutical industry

LA JOLLA, Calif., March 13, 2024 /PRNewswire/ -- CalciMedica Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, last evening presented data from preclinical studies of Auxora™ in acute kidney injury (AKI) at the 29th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) in San Diego, CA. David Basile, Ph.D., Professor of Anatomy, Cell Biology and Physiology at Indiana University, gave an oral and poster presentation entitled "The Store-Operated Calcium Channel Inhibitor Auxora Improves Renal Function Following Ischemia-Induced Acute Kidney Injury in Rats."

Key Points: 
  • In rats with kidney injury akin to Stage 3 AKI, the rats treated with placebo died while those on Auxora survived and showed modest recovery of GFR.
  • We are excited as these studies support clinical observations of Auxora that suggest the drug may be beneficial for AKI patients."
  • The data presented at AKI & CRRT was from a series of studies referred to as Study 1 and Study 2.
  • These results indicate that Auxora has the ability to hasten the recovery of kidney function and improve survival in rat models of AKI.

SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024

Retrieved on: 
Monday, March 11, 2024
Chronic kidney disease, FAAP, Multiple organ dysfunction syndrome, Medical director, Critical care, FDA, CKRT, SCD, Hospital, Risk, Conference, University, SeaStar, Acute kidney injury, AKI, CRRT, Nephrology, Pharmaceutical industry

DENVER, March 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces its sponsorship of an Industry Symposium titled “New Therapies in Pediatric Acute Kidney Injury” on March 13, 2024 at the 29th International Conference on Advances in Critical Care Nephrology – Updates in ICU Medicine: Controversies, Challenges and Solutions (AKI & CRRT 2024). The hybrid in-person and virtual conference is being held March 12-15 in San Diego.

Key Points: 
  • The hybrid in-person and virtual conference is being held March 12-15 in San Diego.
  • “Despite advancements in kidney replacement therapy, mortality rates in children with acute kidney injury (AKI) and multi-organ failure requiring continuous kidney replacement therapy (CKRT) remain at about 50%, and children who survive an AKI episode are at elevated risk of chronic kidney disease.
  • “It’s exciting to have recognized leaders in AKI and nephrology who serve on the SeaStar Medical Scientific Advisory Board participate in this symposium.
  • The discussion will highlight our technology, clinical data and the recent FDA approval of the SCD-PED, the first therapeutic device in our Quelimmune product family,” said Kevin Chung, MD, SeaStar Medical’s Chief Medical Officer.

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Diuretic, Operating cost, Absorption, FDA, Growth, SCD, Cirrhosis, IDE, SeaStar, Nephrology, Webcast, Patient, Pediatrics, CRRT, CRRC, THT, Research, PIK, Pharmaceutical industry

Fourth quarter pediatric revenue grew 35% year over year; 28% increase in utilization and a 49% increase in console sales.

Key Points: 
  • Fourth quarter pediatric revenue grew 35% year over year; 28% increase in utilization and a 49% increase in console sales.
  • Gross margin was 54.4% for the fourth quarter of 2023, compared to 56.9% in the prior-year period, a decrease of 250 basis points.
  • Selling, general and administrative expenses for the fourth quarter of 2023 were $3.6 million, compared to $4.7 million in the prior-year period.
  • Total operating expenses for the fourth quarter of 2023 were $5.0 million, a 15% decrease compared to $5.9 million in the prior-year period.

Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients

Retrieved on: 
Monday, March 4, 2024
DGF, Kidney, KATP, LOS, MD, Critical care, FDA, Food, Conference, Mitochondrion, ODD, Therapy, Patient, AKI, Kidney disease, Diagnosis, CRRT, Kidney transplantation, Pharmaceutical industry

LOS ALTOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that the U.S. Food and Drug Administration has granted orphan drug designation (ODD) to UNI-494 for the prevention of Delayed Graft Function (DGF) in kidney transplant patients.

Key Points: 
  • LOS ALTOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that the U.S. Food and Drug Administration has granted orphan drug designation (ODD) to UNI-494 for the prevention of Delayed Graft Function (DGF) in kidney transplant patients.
  • UNI-494 is a cytoprotective agent that elicits an ischemic preconditioning effect by activating KATP channels in mitochondria to restore mitochondrial function.
  • “We are pleased to announce that the FDA has granted orphan drug designation to UNI-494 for the prevention of delayed graft function after kidney transplantation, an unmet medical need for which there are no FDA-approved drugs,” said Shalabh Gupta, MD, Chief Executive Officer of Unicycive.
  • “Obtaining ODD is an important milestone in the development of UNI-494 that may provide certain tax credits for qualified clinical trials, exemption of user fees, and the potential for seven years of market exclusivity after approval.

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Retrieved on: 
Tuesday, January 30, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Senior, CRRT, AKI, Acute kidney injury, Toll-like receptor 4, TLR4, Conference

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place in San Diego (March 12-15, 2024).

Key Points: 
  • Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place in San Diego (March 12-15, 2024).
  • Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI and hospital acquired infection.
  • Robin Marsden, Senior Vice President of Biology, Revelation Biosciences
    “We are delighted to have the opportunity to present our exciting preclinical data for the prevention of acute kidney injury (AKI),” said James Rolke, Chief Executive Officer of Revelation.
  • “We are grateful to the conference organizers for creating a forum for industry, academia, and key opinion leaders to share data and ideas in this critical area of medicine.”

Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference

Retrieved on: 
Monday, January 29, 2024
LOS, Patient, Therapy, MD, AKI, Kidney disease, Critical care, Conference, CRRT, Acute kidney injury, OLC, Kidney transplantation, Pharmaceutical industry

Shalabh Gupta, MD, Chief Executive Officer of Unicycive, commented, “We are looking forward to presenting data on the efficacy of our second clinical stage program UNI-494 in animal models of delayed graft function, a manifestation of acute kidney injury (AKI) that occurs during kidney transplantation resulting in loss of kidney function.

Key Points: 
  • Shalabh Gupta, MD, Chief Executive Officer of Unicycive, commented, “We are looking forward to presenting data on the efficacy of our second clinical stage program UNI-494 in animal models of delayed graft function, a manifestation of acute kidney injury (AKI) that occurs during kidney transplantation resulting in loss of kidney function.
  • We are also presenting a poster describing our ongoing Phase 1 clinical trial design for UNI-494 in healthy volunteers.
  • Based on the results from this trial, we will determine the best path forward for the program.
  • While our primary focus is on advancing our lead drug, OLC (Oxylanthanum Carbonate) towards a New Drug Application submission, we continue to build a body of data on UNI-494 as it progresses through its first clinical trial.”

Global Continuous Renal Replacement Therapy Market Analysis and Forecast Report 2024-2033 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 5, 2024
Biotechnology, Pharmaceutical, Health, AKI, Prevalence, Competitive landscape, Incidence, Hemofiltration, Renal replacement therapy, Hospice and palliative medicine, Growth, Patient, CRRT, Sepsis, Pharmaceutical industry

The "Global Continuous Renal Replacement Therapy Market: Focus on Modality, Product, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Continuous Renal Replacement Therapy Market: Focus on Modality, Product, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
  • Key Questions Answered in this Report:
    What are the focus segments of the global continuous renal replacement therapy market in the upcoming years?
  • What are the major opportunities for existing market players and new entrants in the global continuous renal replacement therapy market?
  • What are the major opportunities for existing market players and new entrants in the global continuous renal replacement therapy market?